Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation.

Screening for ovarian cancer with MMS is both more effective and more expensive than not screening. Compared to national willingness to pay thresholds, lifetime cost-effectiveness is promising, but there remains considerable uncertainty regarding extrapolated long-term effectiveness.